GSK to Appeal $120M Zantac Verdict
Ticker: GLAXF · Form: 6-K · Filed: Aug 6, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: litigation, legal-settlement, product-liability
TL;DR
GSK lost a Zantac trial in Illinois, jury awarded $120M, company plans to appeal.
AI Summary
GSK plc issued a statement on August 5, 2024, regarding the Zantac (ranitidine) litigation. A jury in an Illinois state court case, the Joiner case, found in favor of the plaintiffs, awarding $120 million in damages. GSK plc stated it will appeal this verdict.
Why It Matters
This verdict represents a significant financial and legal setback for GSK, potentially impacting future litigation outcomes and the company's financial performance.
Risk Assessment
Risk Level: medium — The outcome of this specific litigation could set a precedent for other Zantac-related lawsuits, increasing financial and reputational risk for GSK.
Key Numbers
- $120 million — Damages Awarded (Amount awarded to plaintiffs in the Joiner case)
Key Players & Entities
- GSK plc (company) — Registrant and defendant in Zantac litigation
- Zantac (ranitidine) (product) — Subject of the litigation
- Joiner case (legal_case) — Specific Illinois state court case
- $120 million (dollar_amount) — Damages awarded by the jury
- August 5, 2024 (date) — Date of GSK's statement
FAQ
What was the outcome of the Joiner case regarding Zantac litigation?
A jury in the Joiner case, an Illinois state court trial, found in favor of the plaintiffs and awarded $120 million in damages.
What is GSK's response to the Joiner case verdict?
GSK plc stated that it will appeal the verdict.
When did GSK issue its statement regarding the Zantac litigation?
GSK plc issued its statement on August 5, 2024.
In which court was the Joiner case heard?
The Joiner case was heard in an Illinois state court.
What is the subject of the litigation mentioned in the filing?
The litigation concerns Zantac (ranitidine).
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 15.2 · Accepted 2024-08-06 06:55:45
Filing Documents
- a2686z.htm (6-K) — 33KB
- 0001654954-24-009982.txt ( ) — 34KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: August 06, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc